Cargando…
Predicting Progression-Free Survival Using MRI-Based Radiomics for Patients With Nonmetastatic Nasopharyngeal Carcinoma
Objectives: This study aimed to explore the predictive value of MRI-based radiomic model for progression-free survival (PFS) in nonmetastatic nasopharyngeal carcinoma (NPC). Methods: A total of 327 nonmetastatic NPC patients [training cohort (n = 230) and validation cohort (n = 97)] were enrolled. T...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235342/ https://www.ncbi.nlm.nih.gov/pubmed/32477932 http://dx.doi.org/10.3389/fonc.2020.00618 |
_version_ | 1783535946024615936 |
---|---|
author | Shen, Hesong Wang, Yu Liu, Daihong Lv, Rongfei Huang, Yuanying Peng, Chao Jiang, Shixi Wang, Ying He, Yongpeng Lan, Xiaosong Huang, Hong Sun, Jianqing Zhang, Jiuquan |
author_facet | Shen, Hesong Wang, Yu Liu, Daihong Lv, Rongfei Huang, Yuanying Peng, Chao Jiang, Shixi Wang, Ying He, Yongpeng Lan, Xiaosong Huang, Hong Sun, Jianqing Zhang, Jiuquan |
author_sort | Shen, Hesong |
collection | PubMed |
description | Objectives: This study aimed to explore the predictive value of MRI-based radiomic model for progression-free survival (PFS) in nonmetastatic nasopharyngeal carcinoma (NPC). Methods: A total of 327 nonmetastatic NPC patients [training cohort (n = 230) and validation cohort (n = 97)] were enrolled. The clinical and MRI data were collected. The least absolute shrinkage selection operator (LASSO) and recursive feature elimination (RFE) were used to select radiomic features. Five models [Model 1: clinical data, Model 2: overall stage, Model 3: radiomics, Model 4: radiomics + overall stage, Model 5: radiomics + overall stage + Epstein–Barr virus (EBV) DNA] were constructed. The prognostic performances of these models were evaluated by Harrell's concordance index (C-index). The Kaplan–Meier method was applied for the survival analysis. Results: Model 5 incorporating radiomics, overall stage, and EBV DNA yielded the highest C-indices for predicting PFS in comparison with Model 1, Model 2, Model 3, and Model 4 (training cohorts: 0.805 vs. 0.766 vs. 0.749 vs. 0.641 vs. 0.563, validation cohorts: 0.874 vs. 0.839 vs. 836 vs. 0.689 vs. 0.456). The survival curve showed that the high-risk group yielded a lower PFS than the low-risk group. Conclusions: The model incorporating radiomics, overall stage, and EBV DNA showed better performance for predicting PFS in nonmetastatic NPC patients. |
format | Online Article Text |
id | pubmed-7235342 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-72353422020-05-29 Predicting Progression-Free Survival Using MRI-Based Radiomics for Patients With Nonmetastatic Nasopharyngeal Carcinoma Shen, Hesong Wang, Yu Liu, Daihong Lv, Rongfei Huang, Yuanying Peng, Chao Jiang, Shixi Wang, Ying He, Yongpeng Lan, Xiaosong Huang, Hong Sun, Jianqing Zhang, Jiuquan Front Oncol Oncology Objectives: This study aimed to explore the predictive value of MRI-based radiomic model for progression-free survival (PFS) in nonmetastatic nasopharyngeal carcinoma (NPC). Methods: A total of 327 nonmetastatic NPC patients [training cohort (n = 230) and validation cohort (n = 97)] were enrolled. The clinical and MRI data were collected. The least absolute shrinkage selection operator (LASSO) and recursive feature elimination (RFE) were used to select radiomic features. Five models [Model 1: clinical data, Model 2: overall stage, Model 3: radiomics, Model 4: radiomics + overall stage, Model 5: radiomics + overall stage + Epstein–Barr virus (EBV) DNA] were constructed. The prognostic performances of these models were evaluated by Harrell's concordance index (C-index). The Kaplan–Meier method was applied for the survival analysis. Results: Model 5 incorporating radiomics, overall stage, and EBV DNA yielded the highest C-indices for predicting PFS in comparison with Model 1, Model 2, Model 3, and Model 4 (training cohorts: 0.805 vs. 0.766 vs. 0.749 vs. 0.641 vs. 0.563, validation cohorts: 0.874 vs. 0.839 vs. 836 vs. 0.689 vs. 0.456). The survival curve showed that the high-risk group yielded a lower PFS than the low-risk group. Conclusions: The model incorporating radiomics, overall stage, and EBV DNA showed better performance for predicting PFS in nonmetastatic NPC patients. Frontiers Media S.A. 2020-05-12 /pmc/articles/PMC7235342/ /pubmed/32477932 http://dx.doi.org/10.3389/fonc.2020.00618 Text en Copyright © 2020 Shen, Wang, Liu, Lv, Huang, Peng, Jiang, Wang, He, Lan, Huang, Sun and Zhang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Shen, Hesong Wang, Yu Liu, Daihong Lv, Rongfei Huang, Yuanying Peng, Chao Jiang, Shixi Wang, Ying He, Yongpeng Lan, Xiaosong Huang, Hong Sun, Jianqing Zhang, Jiuquan Predicting Progression-Free Survival Using MRI-Based Radiomics for Patients With Nonmetastatic Nasopharyngeal Carcinoma |
title | Predicting Progression-Free Survival Using MRI-Based Radiomics for Patients With Nonmetastatic Nasopharyngeal Carcinoma |
title_full | Predicting Progression-Free Survival Using MRI-Based Radiomics for Patients With Nonmetastatic Nasopharyngeal Carcinoma |
title_fullStr | Predicting Progression-Free Survival Using MRI-Based Radiomics for Patients With Nonmetastatic Nasopharyngeal Carcinoma |
title_full_unstemmed | Predicting Progression-Free Survival Using MRI-Based Radiomics for Patients With Nonmetastatic Nasopharyngeal Carcinoma |
title_short | Predicting Progression-Free Survival Using MRI-Based Radiomics for Patients With Nonmetastatic Nasopharyngeal Carcinoma |
title_sort | predicting progression-free survival using mri-based radiomics for patients with nonmetastatic nasopharyngeal carcinoma |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235342/ https://www.ncbi.nlm.nih.gov/pubmed/32477932 http://dx.doi.org/10.3389/fonc.2020.00618 |
work_keys_str_mv | AT shenhesong predictingprogressionfreesurvivalusingmribasedradiomicsforpatientswithnonmetastaticnasopharyngealcarcinoma AT wangyu predictingprogressionfreesurvivalusingmribasedradiomicsforpatientswithnonmetastaticnasopharyngealcarcinoma AT liudaihong predictingprogressionfreesurvivalusingmribasedradiomicsforpatientswithnonmetastaticnasopharyngealcarcinoma AT lvrongfei predictingprogressionfreesurvivalusingmribasedradiomicsforpatientswithnonmetastaticnasopharyngealcarcinoma AT huangyuanying predictingprogressionfreesurvivalusingmribasedradiomicsforpatientswithnonmetastaticnasopharyngealcarcinoma AT pengchao predictingprogressionfreesurvivalusingmribasedradiomicsforpatientswithnonmetastaticnasopharyngealcarcinoma AT jiangshixi predictingprogressionfreesurvivalusingmribasedradiomicsforpatientswithnonmetastaticnasopharyngealcarcinoma AT wangying predictingprogressionfreesurvivalusingmribasedradiomicsforpatientswithnonmetastaticnasopharyngealcarcinoma AT heyongpeng predictingprogressionfreesurvivalusingmribasedradiomicsforpatientswithnonmetastaticnasopharyngealcarcinoma AT lanxiaosong predictingprogressionfreesurvivalusingmribasedradiomicsforpatientswithnonmetastaticnasopharyngealcarcinoma AT huanghong predictingprogressionfreesurvivalusingmribasedradiomicsforpatientswithnonmetastaticnasopharyngealcarcinoma AT sunjianqing predictingprogressionfreesurvivalusingmribasedradiomicsforpatientswithnonmetastaticnasopharyngealcarcinoma AT zhangjiuquan predictingprogressionfreesurvivalusingmribasedradiomicsforpatientswithnonmetastaticnasopharyngealcarcinoma |